Ryan, Kellie J.
Skinner, Karen E.
Fernandes, Ancilla W.
Punekar, Rajeshwari S.
Pavilack, Melissa
Walker, Mark S.
VanderWalde, Noam A.
Funding for this research was provided by:
AstraZeneca (N/A)
Article History
Received: 18 December 2018
Accepted: 21 January 2019
First Online: 31 January 2019
Compliance with ethical standards
:
: KJR, AWF, and MP are employed by AstraZeneca and own stock in AstraZeneca. KES and MSW are employed by Vector Oncology. RSP was employed by Vector Oncology during the conduct of the research. NAV reports no conflicts of interest. AstraZeneca sponsored this study and provided financial support for the conduct of the research and for preparation of the article. The sponsor collaborated on the design of the study, interpretation of the analyses, and in the decision to submit the article for publication. The sponsor did not have a direct role in data collection, data analysis, or writing of the report.
: This study was approved by IntegReview institutional review board (Austin, TX) and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study involved retrospective analysis of existing data with no patient intervention or interaction.